Original language | English |
---|---|
Pages (from-to) | e139-e141 |
Journal | International Journal of Dermatology |
Volume | 59 |
Issue number | 5 |
DOIs | |
State | Published - 1 May 2020 |
Externally published | Yes |
Bibliographical note
Funding Information:source: Dr. Gal Markel has the following supports that did not play any role in this manuscript: Advisory: MSD, BMS, Novartis, Biond biologics. Honoraria: MSD, BMS, Novartis, Roche, Medison. Research grants: Novartis, H&S Ventures. IP: Famewave, 4c biomed. Stocks/options: Famewave, 4c biomed, Biond biologics.
Funding
source: Dr. Gal Markel has the following supports that did not play any role in this manuscript: Advisory: MSD, BMS, Novartis, Biond biologics. Honoraria: MSD, BMS, Novartis, Roche, Medison. Research grants: Novartis, H&S Ventures. IP: Famewave, 4c biomed. Stocks/options: Famewave, 4c biomed, Biond biologics.
Funders | Funder number |
---|---|
Novartis |